PEGS Europe Keynotes |Protein and Antibody Engineering Summit

2021 Archived Content

New Modes of T Cell Recognition and Novel Broadly-Expressed T Cell Epitopes by Dissection of Cancer Immunotherapy Success
Andrew Sewell, PhD, Distinguished Research Professor and Wellcome Trust Senior Investigator, Division of Infection and Immunity, Cardiff University School of Medicine
We have developed a successful pipeline for discovering what so-called “orphan T cells” recognise and applied this to dissect what dominant persistent anti-cancer T cells recognise during successful immunotherapy. This work has uncovered a new, unanticipated, mode of T cell recognition. I will describe this new mode of recognition in atomic level detail and describe why and how it might be linked to successful clearance of solid cancers.

The Role of Monoclonal Antibody Therapeutics in Tackling Global Health Challenges
Pauline Williams, CBE, MBBCh, FFPM, FMedSci, Senior Vice President and Head of Global Health R&D, GlaxoSmithKline
Monoclonal antibody therapies have historically been dismissed as viable global health interventions because of cost, supply chain and healthcare system limitations. The global response to the COVID-19 pandemic has demonstrated how disruptive approaches to R&D can transform therapeutic and preventative approaches in a short timescale. There is an increased awareness of the role mAbs can play in addressing public health challenges, including infectious diseases and anti-microbial resistance.

PD-1 Antibodies as Precision Medicine Informed Mono- and Combination Therapies Are Transforming Cancer Care
Roy Baynes, MD, PhD, Senior Vice President & Head, Global Clinical Development; CMO, Merck, Sharp and Dohme

Reprogramming the Tumour Microenvironment: Lessons From the Clinic and Back
Stephen A. Beers, PhD, Professor of Immunology & Immunotherapy, University of Southampton

Protein Quality Control and Research Data Reproducibility: Little Pain, Lots to Gain?
Nick Berrow, Manager, Protein Expression Core Facility, Institute for Research in Biomedicine IRB Barcelona

A Compact Vocabulary of Paratope-Epitope Interactions Enables Predictability of Antibody-Antigen Binding
Victor Greiff, PhD, Associate Professor, Immunology, University of Oslo, Norway

Engineering Antibodies for Next-Generation Cancer Immunotherapy
Christian Klein, PhD, Cancer Immunotherapy Discovery, Roche Innovation Center Zurich, Roche Pharma Research & Early Development, pRED

Treatment of Neuroblastoma with CAR T Cells
Franco Locatelli, MD, PhD, Professor of Pediatrics, Sapienza, University of Rome; Director, Department of Pediatric Hematology and Oncology, IRCCS Ospedale Pediatrico Bambino Gesù

Analytical Ultracentrifugation: An Auxiliary Tool for Vector Characterization
Robert Pletzenauer, Head of Process Analytics, Gene Therapy, Process Development, Takeda

The SHREAD platform: SHielded, REtargeted ADenovirus for Paracrine Delivery of Therapeutics
Andreas G. Plueckthun, PhD, Professor & Head, Biochemistry, University of Zurich

Da Ren Advancing Mass Spectrometry Technology in cGMP Environments
Da Ren, PhD, Scientific Director, Process Development, Amgen Inc.

Self-Assembly of Antibodies in Concentrated Solutions – Insight from Scattering Experiments and Computer Simulations
Peter Schurtenberger, PhD, Professor, Physical Chemistry, Lund University

How Target Biology Drives Bispecific Antibody Product Discovery
Janine Schuurman, PhD, Senior Vice President, Antibody Research & Technology, Research & Innovation, Genmab BV

Third-Generation Methods of Antibody Discovery and Optimisation: In silico Rational Design
Pietro Sormanni, PhD, Royal Society University Research Fellow, Yusuf Hamied Department of Chemistry, University of Cambridge

Robust Production of Optimized Protein-Based Therapeutics with Tailor-Made and Improved Glycosylation
Bjørn Voldborg MSc, Head, National Biologics Facility, DTU Bioengineering, Technical University of Denmark